Orchestra BioMed (NASDAQ:OBIO) Director Buys $34,986.90 in Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Jason Aryeh acquired 8,971 shares of Orchestra BioMed stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $3.90 per share, with a total value of $34,986.90. Following the completion of the purchase, the director owned 117,453 shares in the company, valued at $458,066.70. This represents a 8.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jason Aryeh also recently made the following trade(s):

• On Monday, May 18th, Jason Aryeh acquired 665 shares of Orchestra BioMed stock. The shares were purchased at an average price of $3.75 per share, with a total value of $2,493.75.

Orchestra BioMed Stock Up 3.0%

NASDAQ:OBIO opened at $4.10 on Friday. The firm has a 50-day simple moving average of $4.25 and a two-hundred day simple moving average of $4.27. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $5.42. The firm has a market cap of $245.51 million, a P/E ratio of -4.23 and a beta of 0.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. Analysts predict that Orchestra BioMed Holdings, Inc. will post -1.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on OBIO shares. Weiss Ratings lowered shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Barclays lifted their price target on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, B. Riley Financial reduced their price target on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Orchestra BioMed has an average rating of “Moderate Buy” and an average price target of $13.60.

Institutional Trading of Orchestra BioMed

Several large investors have recently added to or reduced their stakes in OBIO. Alyeska Investment Group L.P. bought a new stake in Orchestra BioMed during the third quarter valued at approximately $3,386,000. Pathstone Holdings LLC bought a new stake in Orchestra BioMed during the third quarter valued at approximately $2,495,000. Vanguard Group Inc. grew its position in Orchestra BioMed by 28.0% during the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after buying an additional 324,558 shares during the period. Simplify Asset Management Inc. bought a new stake in Orchestra BioMed during the first quarter valued at approximately $932,000. Finally, 683 Capital Management LLC bought a new stake in Orchestra BioMed during the fourth quarter valued at approximately $847,000. 53.20% of the stock is currently owned by institutional investors.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.